In:
PLOS ONE, Public Library of Science (PLoS), Vol. 18, No. 6 ( 2023-6-13), p. e0287017-
Abstract:
It has been argued that persons with severe mental illness (SMI) receive poorer treatment for somatic comorbidities. This study assesses the treatment rates of glucose-lowering and cardiovascular medications among persons with incident type 2 diabetes (T2D) and SMI compared to persons with T2D without SMI. We identified persons ≥30 years old with incident diabetes (HbA 1c ≥ 48 mmol/mol and/or glucose ≥ 11.0 mmol/L) from 2001 through 2015 in the Copenhagen Primary Care Laboratory (CopLab) Database. The SMI group included persons with psychotic, affective, or personality disorders within five years preceding the T2D diagnosis. Using a Poisson regression model, we calculated the adjusted rate ratios (aRR) for the redemption of various glucose-lowering and cardiovascular medications up to ten years after T2D diagnosis. We identified 1,316 persons with T2D and SMI and 41,538 persons with T2D but no SMI. Despite similar glycemic control at diagnosis, persons with SMI redeemed a glucose-lowering medication more often than persons without SMI in the period 0.5–2 years after the T2D diagnosis; for example, the aRR was 1.05 (95% CI 1.00–1.11) in the period 1.5–2 years after the T2D diagnosis. This difference was mainly driven by metformin. In contrast, persons with SMI were less often treated with cardiovascular medications during the first 3 years after T2D diagnosis, e.g., in the period 1.5–2 years after T2D diagnosis, the aRR was 0.96 (95% CI 0.92–0.99). For people with SMI in addition to T2D, metformin is more likely to be used in the initial years after T2D diagnosis, while our results suggest potential room for improvement regarding the use of cardiovascular medications.
Type of Medium:
Online Resource
ISSN:
1932-6203
DOI:
10.1371/journal.pone.0287017
DOI:
10.1371/journal.pone.0287017.g001
DOI:
10.1371/journal.pone.0287017.g002
DOI:
10.1371/journal.pone.0287017.g003
DOI:
10.1371/journal.pone.0287017.t001
DOI:
10.1371/journal.pone.0287017.s001
DOI:
10.1371/journal.pone.0287017.s002
DOI:
10.1371/journal.pone.0287017.s003
DOI:
10.1371/journal.pone.0287017.s004
DOI:
10.1371/journal.pone.0287017.s005
DOI:
10.1371/journal.pone.0287017.s006
DOI:
10.1371/journal.pone.0287017.s007
DOI:
10.1371/journal.pone.0287017.s008
DOI:
10.1371/journal.pone.0287017.s009
DOI:
10.1371/journal.pone.0287017.s010
DOI:
10.1371/journal.pone.0287017.s011
DOI:
10.1371/journal.pone.0287017.r001
DOI:
10.1371/journal.pone.0287017.r002
DOI:
10.1371/journal.pone.0287017.r003
DOI:
10.1371/journal.pone.0287017.r004
DOI:
10.1371/journal.pone.0287017.r005
DOI:
10.1371/journal.pone.0287017.r006
Language:
English
Publisher:
Public Library of Science (PLoS)
Publication Date:
2023
detail.hit.zdb_id:
2267670-3
Permalink